Literature DB >> 20635993

Immunotherapy of viral infections.

Nagendra R Hegde1, Pavuluri Panduranga Rao, Jagadeesh Bayry, Srinivas V Kaveri.   

Abstract

Among the microorganisms that cause diseases of medical or veterinary importance, the only group that is entirely dependent on the host, and hence not easily amenable to therapy via pharmaceuticals, is the viruses. Since viruses are obligate intracellular pathogens, and therefore depend a great deal on cellular processes, direct therapy of viral infections is difficult. Thus, modifying or targeting nonspecific or specific immune responses is an important aspect of intervention of ongoing viral infections. However, as a result of the unavailability of effective vaccines and the extended duration of manifestation, chronic viral infections are the most suitable for immunotherapies. We present an overview of various immunological strategies that have been applied for treating viral infections after exposure to the infectious agent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20635993     DOI: 10.2217/imt.09.26

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  3 in total

Review 1.  Ayurveda Rasayana as antivirals and immunomodulators: potential applications in COVID-19.

Authors:  Rajeshwari Singh; Sumeet Goel; Pascale Bourgeade; Lotfi Aleya; Devesh Tewari
Journal:  Environ Sci Pollut Res Int       Date:  2021-09-07       Impact factor: 5.190

2.  SARS-Cov-2 pneumonia and concurrent myelodysplasia complicated by Pseudomonas aeruginosa over-infection.

Authors:  Aldo Pezzuto; Antonella Tammaro; Giuseppe Tonini; Giulia Conforti; Francesca Falangone; Valerio Spuntarelli; Antonella Teggi; Alfredo Pennica
Journal:  J Virol Methods       Date:  2021-12-10       Impact factor: 2.014

3.  Prevalence of Neutralizing Antibodies to Japanese Encephalitis Virus among High-Risk Age Groups in South Korea, 2010.

Authors:  Eun Ju Lee; Go-Woon Cha; Young Ran Ju; Myung Guk Han; Won-Ja Lee; Young Eui Jeong
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.